Targeted induction of bone marrow mesenchymal stem cells to have effectiveness on diabetic pancreatic restoration

  • Jing Zhang
  • Ruonan Mao
  • Xinyu Wang
  • Kun Liu
  • Qi Geng
  • Yijin Yu
  • Yanning LiEmail author
  • Jinsheng QiEmail author


Although bone marrow-derived mesenchymal stem cells (BMSCs) have been reported to be effective for the attenuation of diabetes, they have limitations. Whether BMSCs can be target-induced by pancreatic stem cells (PSCs) to have effectiveness for the restoration of diabetic islet injury was unknown. In this study, based on their successful isolation and cultivation, BMSCs were co-cultured with PSCs. The pancreatic stem cells markers, Nestin and Neurogenin3 in co-cultured BMSCs were detected to evaluate the target-induction effects. After the diabetic rats were intravenously injected with the target-induced BMSCs, general indicators and islet morphology were detected. The islet insulin generation, and serum insulin and C-peptide contents were measured. It was found that after co-culture, the mRNA expressions, protein contents and distributions of Nestin and Neurogenin3, were dramatically high in BMSCs, indicating that they were successfully target-induced to pancreatic stem-like cells. Furthermore, the target-induced BMSCs had beneficial effects on serum glycated albumin levels and glycogen contents as well as islet morphology of the diabetic rats. Besides elevation of islet insulin generation, the target-induced BMSCs had significant effect on serum insulin and C-peptide contents. In conclusion, BMSCs could be target-induced by PSCs to have effectiveness on the pancreatic restoration of diabetic rats.


Bone marrow mesenchymal stem cells Pancreatic stem cells Targeted induction Pancreatic restoration 


Financial funding

This work was supported by Grants from the National Natural Science Foundation of China (81470595 and 81600384) and the Hebei Natural Science Foundation (H2015206101).

Compliance with ethical standards

Experiment protocol followed the guidelines established by the Ethics Review Committee for Animal Experimentation of Hebei Medical University.

Conflict of interest

The authors declare that they have no competing interests.

Supplementary material

11626_2019_364_Fig8_ESM.png (12.2 mb)

(PNG 12444 kb)

High Resolution Image (TIF 2974 kb)


  1. Aguayo-Mazzucato C, Bonner-Weir S (2018) Pancreatic β cell regeneration as a possible therapy for diabetes. Cell Metab 27(1):57–67Google Scholar
  2. Bai C, Gao Y, Li X, Wang K, Xiong H, Shan Z (2017) MicroRNAs can effectively induce formation of insulin-producing cells from mesenchymal stem cells. J Tissue Eng Regen Med 11(12):3457–3468Google Scholar
  3. Bai C, Gao Y, Zhang X, Yang W, Guan W (2018) Melatonin promotes self-renewal of nestin-positive pancreatic stem cells through activation of the MT2/ERK/SMAD/nestin axis. Artif Cells Nanomed Biotechnol 46(1):62–74Google Scholar
  4. Bernal A, Arranz L (2018) Nestin-expressing progenitor cells: function, identity and therapeutic implications. Cell Mol Life Sci 75(12):2177–2195Google Scholar
  5. Błogowski W, Bodnarczuk T, Starzyńska T (2016) Concise review: pancreatic cancer and bone marrow-derived stem cells. Stem Cells Transl Med 5(7):938–945Google Scholar
  6. Cheng CW, Villani V, Buono R, Wei M, Kumar S, Yilmaz OH (2017) Fasting-mimicking diet promotes ngn3-driven β-cell regeneration to reverse diabetes. Cell 168(5):775–788 e12 Google Scholar
  7. Cleaver O (2017) β cell renewal versus differentiation: slow and steady wins the race. Dev Cell 41(3):223–225Google Scholar
  8. Desai T, Shea LD (2017) Advances in islet encapsulation technologies. Nat Rev Drug Discov 16(5):338–350Google Scholar
  9. Dong S, Wu H (2018) Regenerating β cells of the pancreas - potential developments in diabetes treatment. Expert Opin Biol Ther 18(2):175–185Google Scholar
  10. El-Asfar R, Kamal M, Abd El-Razek R, El-Demerdash E, El-Mesallamy H (2018) Obestatin can potentially differentiate Wharton’s jelly mesenchymal stem cells into insulin-producing cells. Cell Tissue Res 372(1):91–98Google Scholar
  11. Ellis C, Ramzy A, Kieffer TJ (2017) Regenerative medicine and cell-based approaches to restore pancreatic function. Nat Rev Gastroenterol Hepatol 14(10):612–628Google Scholar
  12. Hayward JA, Ellis CE, Seeberger K, Lee T, Salama B, Mulet-Sierra A (2017) Cotransplantation of mesenchymal stem cells with neonatal porcine islets improve graft function in diabetic mice. Diabetes 66(5):1312–1321Google Scholar
  13. He Y, Chen D, Yang L, Hou Q, Ma H, Xu X (2018) The therapeutic potential of bone marrow mesenchymal stem cells in premature ovarian failure. Stem Cell Res Ther 9(1):263Google Scholar
  14. Hedhli J, Konopka CJ, Schuh S, Bouvin H, Cole JA, Huntsman HD (2017) Multimodal assessment of mesenchymal stem cell therapy for diabetic vascular complications. Theranostics 7(16):3876–3888Google Scholar
  15. Ikemoto T, Feng R, Shimada M, Saito Y, Iwahashi S, Morine Y (2018) A new 2-step acceleration protocol using a histone deacetylase inhibitor to generate insulin-producing cells from adipose-derived mesenchymal stem cells. Pancreas 47(4):477–481Google Scholar
  16. Kalra K, Chandrabose ST, Ramasamy TS, Kasim NHBA (2018) Advances in generation of functional β-cells from induced pluripotent stem cells as a cure for diabetes mellitus. Curr Drug Targets 19(13):1463–1477Google Scholar
  17. Lee HY, Hong IS (2017) Double-edged sword of mesenchymal stem cells: Cancer-promoting versus therapeutic potential. Cancer Sci 108(10):1939–1946Google Scholar
  18. Li HT, Jiang FX, Shi P, Zhang T, Liu XY, Lin XW (2017) In vitro reprogramming of rat bmMSCs into pancreatic endocrine-like cells. In Vitro Cell Dev Biol Anim 53(2):157–166Google Scholar
  19. Li Y, Li X, He K, Li B, Liu K, Qi J (2018a) C-peptide prevents NF-κB from recruiting p300 and binding to the inos promoter in diabetic nephropathy. FASEB J 32(4):2269–2279Google Scholar
  20. Li Y, Liu J, Liao G, Zhang J, Chen Y, Li L (2018b) Early intervention with mesenchymal stem cells prevents nephropathy in diabetic rats by ameliorating the inflammatory microenvironment. Int J Mol Med 41(5):2629–2639Google Scholar
  21. Li Y, Zong Y, Xiao Z, Zhu M, Xiao H, Qi J (2016) Developmental stage-specific embryonic induction of HepG2 cell differentiation. Dig Dis Sci 61(4):1098–1106Google Scholar
  22. Loo LSW, Lau HH, Jasmen JB, Lim CS, Teo AKK (2018) An arduous journey from human pluripotent stem cells to functional pancreatic β cells. Diabetes Obes Metab 20(1):3–13Google Scholar
  23. Masoud MS, Qasim M, Ali MU (2017) Translating the potential of stem cells for diabetes mellitus: challenges and opportunities. Curr Stem Cell Res Ther 12(8):611–623Google Scholar
  24. Memon B, Karam M, Al-Khawaga S, Abdelalim EM (2018) Enhanced differentiation of human pluripotent stem cells into pancreatic progenitors co-expressing PDX1 and NKX61. Stem Cell Res Ther 9(1):15Google Scholar
  25. Mihara Y, Matsuura K, Sakamoto Y, Okano T, Kokudo N, Shimizu T (2017) Production of pancreatic progenitor cells from human induced pluripotent stem cells using a three-dimensional suspension bioreactor system. J Tissue Eng Regen Med 11(11):3193–3201Google Scholar
  26. Moreira A, Kahlenberg S, Hornsby P (2017) Therapeutic potential of mesenchymal stem cells for diabetes. J Mol Endocrinol 59(3):109–120Google Scholar
  27. Murai N, Ohtaki H, Watanabe J, Xu Z, Sasaki S, Yagura K (2017) Intrapancreatic injection of human bone marrow-derived mesenchymal stem/stromal cells alleviates hyperglycemia and modulates the macrophage state in streptozotocin-induced type 1 diabetic mice. PLoS One 12(10):e0186637Google Scholar
  28. Pan G, Hao H, Liu J (2018) Induction of hepatocytes-derived insulin-producing cells using small molecules and identification of microRNA profiles during this procedure. Biochem Biophys Res Commun 498(3):646–653Google Scholar
  29. Ren L, Yang H, Cui Y, Xu S, Sun F, Tian N (2017) Autophagy is essential for the differentiation of porcine PSCs into insulin-producing cells. Biochem Biophys Res Commun 488(3):471–476Google Scholar
  30. Richardson T, Barner S, Candiello J, Kumta PN, Banerjee I (2016) Capsule stiffness regulates the efficiency of pancreatic differentiation of human embryonic stem cells. Acta Biomater 35:153–165Google Scholar
  31. Saber N, Bruin JE, O’Dwyer S, Schuster H, Rezania A, Kieffer TJ (2018) Sex differences in maturation of human embryonic stem cell-derived beta cells in mice. Endocrinology 159(4):1827–1841Google Scholar
  32. Shao D, Wang C, Sun Y, Cui L (2018) Effects of oral implants with miR-122-modified cell sheets on rat bone marrow mesenchymal stem cells. Mol Med Rep 17(1):1537–1544Google Scholar
  33. Sharma A, Rani R (2017) Do we really need to differentiate mesenchymal stem cells into insulin-producing cells for attenuation of the autoimmune responses in type 1 diabetes: immunoprophylactic effects of precursors to insulin-producing cells. Stem Cell Res Ther 8(1):167Google Scholar
  34. Sheets TP, Park KE, Park CH, Swift SM, Powell A, Donovan DM (2018) Targeted mutation of ngn3 gene disrupts pancreatic endocrine cell development in pigs. Sci Rep 8(1):3582Google Scholar
  35. Sneddon JB, Tang Q, Stock P, Bluestone JA, Roy S, Desai T, Hebrok M (2018) Stem cell therapies for treating diabetes: progress and remaining challenges. Cell Stem Cell 22(6):810–823Google Scholar
  36. Sui L, Danzl N, Campbell SR, Viola R, Williams D, Xing Y (2018) β-cell replacement in mice using human type 1 diabetes nuclear transfer embryonic stem cells. Diabetes 67(1):26–35Google Scholar
  37. Sun X, Hao H, Han Q, Song X, Liu J, Dong L, Han W, Mu Y (2017) Human umbilical cord-derived mesenchymal stem cells ameliorate insulin resistance by suppressing NLRP3 inflammasome-mediated inflammation in type 2 diabetes rats. Stem Cell Res Ther 8(1):241Google Scholar
  38. Thakkar UG, Vanikar AV, Trivedi HL (2017) Stem cells: an emerging novel therapeutic for type-1 diabetes mellitus. Diabetes Res Clin Pract 130:130–132Google Scholar
  39. Trott J, Tan EK, Ong S, Titmarsh DM, Denil SLIJ, Giam M (2017) Long-term culture of self-renewing pancreatic progenitors derived from human pluripotent stem cells. Stem Cell Reports 8(6):1675–1688Google Scholar
  40. Wang Y, Dorrell C, Naugler WE, Heskett M, Spellman P, Li B (2018) Long-term correction of diabetes in mice by in vivo reprogramming of pancreatic ducts. Mol Ther 26(5):1327–1342Google Scholar
  41. Xie L, Zeng X, Hu J, Chen Q (2015) Characterization of Nestin, a selective marker for bone marrow derived mesenchymal stem cells. Stem Cells Int 2015:762098Google Scholar
  42. Xing XK, Feng HG, Yuan ZQ (2016) Differentiation of bone mesenchymal stem cells into hepatocyte-like cells induced by liver tissue homogenate. Genet Mol Res 15(3)Google Scholar
  43. Zang L, Hao H, Liu J, Li Y1, Han W, Mu Y (2017) Mesenchymal stem cell therapy in type 2 diabetes mellitus. Diabetol Metab Syndr 9:36Google Scholar

Copyright information

© The Society for In Vitro Biology 2019

Authors and Affiliations

  1. 1.Department of Biochemistry, Hebei Key Laboratory of Medical BiotechnologyHebei Medical UniversityShijiazhuangPeople’s Republic of China
  2. 2.Department of Molecular Biology, Hebei Key Lab of Laboratory Animal ScienceHebei Medical UniversityShijiazhuangPeople’s Republic of China

Personalised recommendations